Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SuperGen, a pharmaceutical company engaged in the discovery and development of cancer therapies, has reported that Gregory Berk, chief medical officer, has left the company.
Subscribe to our email newsletter
Michael Young, a current member of the SuperGen board of directors and chairman and chief scientific officer of Strategic Healthcare Development, will serve as SuperGen’s interim chief medical advisor, consulting to James Manuso, president and CEO.
Dr Young has served as a non-executive director since September 2002. Prior to joining the company’s board of directors, Dr Young served as executive director, and chief scientific officer, for London-based Medeva and subsequently Celltech, both European biotechnology companies, where he was responsible for research and strategic product development.
Dr Manuso will oversee both clinical and regulatory development until a replacement for Dr Berk can be found. A global search for a new chief medical officer has been initiated.
Clinical operations will continue to report to Gavin Choy, vice president of clinical operations, and regulatory and quality affairs will continue to report to David Smith, vice president of regulatory and quality affairs. During the search for a new chief medical officer, Dr Choy and Dr Smith will report directly to Dr Manuso. SuperGen has two products currently in clinical development.